Abstract
Diffuse large B‐cell lymphoma (DLBCL) is the most common subtype of non‐Hodgkin lymphoma (NHL) and is a clinical, pathological, and molecular heterogeneous disease with highly variable clinical outcomes. Currently, valid prognostic biomarkers in DLBCL are still lacking. To optimize targeted therapy and improve the prognosis of DLBCL, the performance of proposed biomarkers needs to be evaluated in multiple cohorts, and new biomarkers need to be investigated in large datasets. Here, we developed a consensus Online Survival analysis web server for Diffuse Large B‐Cell Lymphoma, abbreviated OSdlbcl, to assess the prognostic value of individual gene. To build OSdlbcl, we collected 1100 samples with gene expression profiles and clinical follow‐up information from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. In addition, DNA mutation data were also collected from the TCGA database. Overall survival (OS), progression‐free survival (PFS), disease‐specific survival (DSS), disease‐free interval (DFI), and progression‐free interval (PFI) are important endpoints to reflect the survival rate in OSdlbcl. Moreover, clinical features were integrated into OSdlbcl to allow data stratifications according to the user's special needs. By inputting an official gene symbol and selecting desired criteria, the survival analysis results can be graphically presented by the Kaplan‐Meier (KM) plot with hazard ratio (HR) and log‐rank p value. As a proof‐of‐concept demonstration, the prognostic value of 23 previously reported survival associated biomarkers, such as transcription factors FOXP1 and BCL2, was evaluated in OSdlbcl and found to be significantly associated with survival as reported (HR = 1.73, P < .01; HR = 1.47, P = .03, respectively). In conclusion, OSdlbcl is a new web server that integrates public gene expression, gene mutation data, and clinical follow‐up information to provide prognosis evaluations for biomarker development for DLBCL. The OSdlbcl web server is available at https://bioinfo.henu.edu.cn/DLBCL/DLBCLList.jsp.
Highlights
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma (NHL), accounting for 30%-40% of the NHL.[1,2] DLBCL is a clinical, pathological, and molecular heterogeneous disease, patients of which have highly variable clinical outcomes.[3]
Independent validation across different cohorts is of great importance for biomarker development, and OSdlbcl is a web server that could facilitate the cross-validation of the prognostic value of biomarkers across seven DLBCL cohorts
DLBCL is a heterogeneous disease with highly variable clinical outcomes.[3]
Summary
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma (NHL), accounting for 30%-40% of the NHL.[1,2] DLBCL is a clinical, pathological, and molecular heterogeneous disease, patients of which have highly variable clinical outcomes.[3]. The current complex classification of DLBCL is presented in World Health Organization (WHO).[4,5]. This disease is curable, 20%-30% of DLBCL patients still experience relapse or refractory disease.[6,7]. Prognostic biomarkers are being investigated to optimize targeted therapy and to predict the prognosis of high-risk DLBCL patients.[8]. More reliable biomarkers with high repeatability and predictive power to diagnose high-risk patients are needed to facilitate the development of alternative treatment strategies for DLBCL.[9]. Despite the availability of numerous expression data and the corresponding clinical information in the public database to date, a web server or tool that could quickly evaluate the prognostic value of potential DLBCL biomarkers is still lacking
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
